Objective To analyze the relationship between serum PECAM-1 and IGF-1 levels and the clinical significance and prognosis of patients with advanced gastric cancer.
Methods The serum levels of PECAM-1 and IGF of 18 patients with advanced gastric cancer were detected by using ELISA before chemotherapy. T-test comparison was used to analyze the correlation between serum PECAM-1 and IGF-1 levels and clinicopathologic feature and survival.
Results ① Among the 18 patients. The median overall survival time (mOS) was 460 days. ② There was no significant difference between serum PECAM-1 and IGF-1 expression levels and clinicopathologic feature, including gender (men and women), age (>60 years and< 60 years), pathological type (adenocarcinoma or Signet ring cell carcinoma), and previous radical gastrectomy. ③ No statistically significant difference between the serum mean concentrations of IGF-1 in these died and alive patients(
P=0.780). The mean PECAM-1 value between survivors and the dead patients, approaching statistical differences (
P=0.050). ④ According to the average level of PECAM-1, patients were divided into two groups (PECAM-1 high group, PECAM-1 low group). The results show that the mOS of the PECAM-1 high group was 283 days, significantly shorter than PECAM-1 low group, which was 484 days,
P=0.035. ⑤ According to the average level of IGF-1, patients were divided into two groups (IGF-1 high group, IGF-1 low group). Similarly, the mOS of the IGF-1 high group was 226 days, significantly shorter than IGF-1 low group, which was 357 days(
P=0.030).
Conclusion ① Here is no correlation between serum PECAM-1 and IGF-1 expression levels and clinicopathologic feature in advanced gastric cancer patients. ② He serum PECAM-1 and IGF-1 expression levels are related to the patient's prognosis and survival in advanced gastric cancer patients. The prognosis and survival is adversely affected in patients with high serum PECAM-1 and IGF-1 concentrations.
DownLoad: